Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
NCT00408304 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2006-12-06
Summary
The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.
Conditions
- Chronic Hepatitis C
Interventions
- DRUG
-
omega-3 fatty acid
Sponsors & Collaborators
-
Bnai Zion Medical Center
lead OTHER_GOV
Principal Investigators
-
Elad Schiff, MD · affiliated with Bnai Zion MC
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-12-31
- Completion
- 2007-12-31
Countries
- Israel
Study Locations
More Related Trials
-
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
NCT00788918 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
NCT00166296 ·Status: COMPLETED ·Phase: PHASE2
-
Neuropsychiatric Effects of Interferon-Alpha and Ribavirin
NCT00001547 ·Status: COMPLETED
-
Psychobiological Characterization of Depression in Hepatitis C
NCT01492478 ·Status: UNKNOWN
-
The Effect of Antiviral Therapy With Pegylated Interferon-alpha on Auditory Disability
NCT01265693 ·Status: COMPLETED
-
Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
NCT01465919 ·Status: TERMINATED ·Phase: PHASE4
-
Hepatitis C Translating Initiatives for Depression Into Effective Solutions
NCT01143896 ·Status: COMPLETED ·Phase: NA
-
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
NCT00136318 ·Status: COMPLETED ·Phase: PHASE3
-
Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C
NCT00209118 ·Status: COMPLETED ·Phase: NA
-
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
NCT03490097 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability
NCT01957319 ·Status: COMPLETED ·Phase: PHASE3
-
Reducing Depressive Symptoms During HCV Therapy: A Randomized Study
NCT00495768 ·Status: UNKNOWN ·Phase: NA
-
Natural History of Hepatitis C in Patients With Normal Liver Tests
NCT00187473 ·Status: COMPLETED
-
Overcoming Psychiatric Barriers to the Treatment of Hepatitis C
NCT00407732 ·Status: COMPLETED ·Phase: NA
-
Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?
NCT01159613 ·Status: COMPLETED
-
Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C
NCT00643695 ·Status: COMPLETED ·Phase: NA
-
Anticipated and Perceived Benefits Following Hepatitis C Treatment
NCT03000023 ·Status: COMPLETED
-
Treatment of Hepatitis c by Using Direct-acting Antiviral
NCT05372874 ·Status: UNKNOWN
-
Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
NCT00871845 ·Status: TERMINATED ·Phase: NA
-
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
NCT03402165 ·Status: UNKNOWN ·Phase: PHASE4
-
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
NCT00136214 ·Status: COMPLETED
-
Vitamin D Treatment in Patients With Chronic Hepatitis C
NCT00804752 ·Status: UNKNOWN ·Phase: NA
-
Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
NCT00948220 ·Status: COMPLETED ·Phase: PHASE4
-
Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents
NCT03894696 ·Status: UNKNOWN
-
Hepatitis C Treatment and Atherosclerosis
NCT00659256 ·Status: COMPLETED